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Ataxia oculomotor apraxia type 2 (AOA2) is a rare autosomal reces-
sive disorder characterized by cerebellar 
atrophy, peripheral neuropathy, loss of 
Purkinje cells and elevated α-fetoprotein. 
AOA2 is caused by mutations in the 
SETX gene that codes for the high molec-
ular weight protein senataxin. Mutations 
in this gene also cause dominant neuro-
degenerative disorders. Similar to that 
observed for other autosomal recessive 
ataxias, this protein protects the integ-
rity of the genome against oxidative and 
other forms of DNA damage to reduce 
the risk of neurodegeneration. Senataxin 
functions in transcription termination 
and RNA splicing and it has been shown 
to resolve RNA/DNA hybrids (R-loops) 
that arise at transcription pause sites or 
when transcription is blocked. Recent 
data suggest that this protein functions at 
the interface between transcription and 
DNA replication to minimise the risk of 
collision and maintain genome stability. 
Our recent data using SETX gene-dis-
rupted mice revealed that male mice were 
defective in spermatogenesis and were 
infertile. DNA double strand-breaks per-
sisted throughout meiosis and crossing-
over failed in SETX mutant mice. These 
changes can be explained by the accumu-
lation of R-loops, which interfere with 
Holiday junctions and crossing-over. We 
also showed that senataxin was localized 
to the XY body in pachytene cells and 
was involved in transcriptional silencing 
of these chromosomes. While the defect 
in meiotic recombination was striking in 
these animals, there was no evidence of 
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neurodegeneration as observed in AOA2 
patients. We discuss here potentially dif-
ferent roles for senataxin in proliferating 
and post-mitotic cells.
Autosomal recessive cerebellar ataxias 
are a class of progressive neurodegenera-
tive disorders that result from cerebellar 
atrophy and spinal tract dysfunction.1 
One of these, ataxia oculomotor apraxia 
type 2 (AOA2) is characterized by pro-
gressive cerebellar atrophy and periph-
eral neuropathy, oculomotor apraxia and 
elevated α-fetoprotein serum levels, with 
an onset between 10–20 y of age.2-4 Brain 
MRI reveals diffuse cerebellar atrophy 
and electroneuromyography confirms the 
peripheral neuropathy.4 The major clinical 
features of this disorder are shown in Table 
1. In a post-mortem AOA2 case, Criscuolo 
et al.5 observed reduced brain size and cer-
ebellar atrophy which was most evident at 
the level of the vermis and anterior lobe; 
the cerebellar cortex had marked loss of 
Purkinje cells and brainstem and spinal 
cord were slightly reduced. Thus, as with 
other autosomal recessive ataxias, pathol-
ogy in the cerebellum features strongly. 
However, unlike that for the related disor-
der ataxia telangiectasia (A-T), there is no 
evidence of increased cancer susceptibility 
in AOA2.
The gene mutated in AOA2 was ini-
tially mapped to chromosome 9q34 and 
subsequently identified as SETX.6 SETX 
is predicted to code for a 2,667 amino 
acid protein (senataxin) that contains a 
highly conserved C-terminal seven-motif 
domain found in the superfamily 1 of 
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and the cells had elevated levels of oxida-
tive DNA damage.8 In support of a role for 
senataxin in the DNA damage response, it 
has also been demonstrated that telomere 
length is constitutively reduced in AOA2 
lymphocytes and the rate of telomere 
shortening by DNA damage is increased 
in these cells.14 Interaction of Sen1p with 
Rnt1p (an endoribonuclease required for 
RNA maturation) suggested that Sen1p 
is also involved in RNA processing and 
transcription.13 We provided evidence for 
a similar role in human cells by identi-
fying novel senataxin-interacting pro-
teins, the majority of which are involved 
in transcription and RNA processing, 
including RNA polymerase II.15 Binding 
of RNA polymerase II to candidate genes 
was significantly reduced in senataxin 
deficient cells and this was accompanied 
by decreased transcription of these genes, 
suggesting a role for senataxin in the 
regulation/modulation of transcription. 
RNA polymerase II-dependent transcrip-
tion termination was defective in cells 
depleted of senataxin in keeping with the 
observed interaction of senataxin with 
poly(A) binding proteins 1 and 2. Splicing 
mutation, causing a cerebellar phenotype 
termed tremor-ataxia syndrome, has been 
described for a mother and daughter. 
These patients showed cerebellar atrophy, 
oculomotor defects and tremor but no evi-
dence of peripheral neuropathy or pyrami-
dal signs.11 In short, mutations in SETX 
can give rise to both dominant and reces-
sive disorders with some overlap in fea-
tures. A greater insight into the function 
of senataxin and the proteins it interacts 
with will help to resolve the quandary of 
several distinct disorders from mutations 
in a single gene.
Senataxin shares extensive homology 
with the yeast Saccharomyces cerevisiae 
splicing endonuclease 1 protein (Sen1p), 
which possesses helicase activity, and is 
involved in the processing of tRNA, rRNA, 
small nuclear and small nucleolar RNA.12 
Sen1p also interacts with Rad2, which is 
required for DNA repair, suggesting that 
the protein may be involved in protecting 
the genome.13 We demonstrated that this 
might also be the case for senataxin by 
showing that AOA2 patient cells display 
sensitivity to DNA damaging agents such 
as H
2
O
2
, camptothecin and mitomycin C 
DNA/RNA helicases and an N-terminal 
domain important for protein-protein 
interaction.7,8 Generally speaking, muta-
tions in a single gene, such as SETX, gives 
rise to one syndrome, which, of course, 
may show heterogeneity depending on 
the nature and localization of the muta-
tions. In the case of SETX, up to 4 dif-
ferent syndromes are associated with 
mutations in this gene (Table 2). Juvenile 
amyotrophic lateral sclerosis (ALS4) is 
a form of juvenile ALS characterized by 
distal muscle weakness and atrophy, nor-
mal sensation and pyramidal tract signs. 
The ALS4 locus maps to chromosome 
9q34. Chen et al.9 detected missense 
mutations in a single allele in the SETX 
gene (which maps to this locus) which 
segregated with the disease. Subsequent 
studies have detected SETX mutations in 
additional ALS4 patients. Heterozygous 
SETX gene mutations were also detected 
in patients with autosomal dominant 
proximal spinal muscular atrophy.10 These 
patients showed proximal and distal mus-
cular atrophy and pareses. While there 
was overlap with ALS4, this appeared to 
be a discrete entity. A dominant SETX 
Table 1. Ataxia Oculomotor Apraxia type 2 
(AOA2): clinical Features
Onset second decade
diffuse cerebellar atrophy (mri)
Peripheral neuropathy
early loss of reflexes
loss of Purkinje cells
Oculomotor apraxia
extra-neurological features of A-t missing but 
α-fetoprotein elevated
Autosomal recessive cerebellar ataxia
Table 2. mutations in SETX give rise to different neurodegenerative disorders
Disorder Age of onset (yr) Major Clinical Phenotype Gene/Protein Inheritance References
Ataxia oculomotor apraxia type 2 (AOA2) 10–20 cerebellar ataxia with peripheral 
neuropathy
Setx/senataxin recessive 1–5
tremor ataxia syndrome (tAS) 3, 13* cerebellar ataxia without peripheral 
neuropathy
Setx/senataxin dominant 11
Juvenile Amyotrophic lateral sclerosis 
(AlS4)
14** limb weakness and severe muscle 
wasting
Setx/senataxin dominant 9
Autosomal dominant proximal spinal mus-
cular atrophy (AdSmA)
10–20 muscular atrophy and weakness Setx/senataxin dominant 10
*Age of onset for daughter and mother. **Average age of onset.
Figure 1. r-loop structure. r-loops form at sites when the rnA polymerase complex encoun-
ters G-rich sequences such as those found at transcription pause sites, cpG islands in promoter 
regions, repeat sequences and telomeric regions.31,32 Pairing of the nascent rnA remains with the 
ssdnA region behind the elongating rnA polymerase complex leads to r-loop (dnA/rnA hybrid) 
formation.
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AOA2 patients is progressive neurodegen-
eration in post-mitotic tissue. Under those 
conditions, ongoing transcription will not 
encounter DNA replication forks. What 
then is the role of senataxin in the brain? 
Vantaggiato et al.23 provided evidence that 
senataxin plays a role in neuritogenesis 
and cytoprotection during neuronal dif-
ferentiation which is mediated by fibro-
blast growth factor 8. However, since this 
is a progressive disease, it is unlikely that 
the role of senataxin is restricted to devel-
opment. To address this further, we dis-
rupted the SETX gene in a mouse model 
for AOA2, which was the subject matter 
of our recent publication.24 Unfortunately, 
we did not observe a neurodegenerative 
phenotype in the Setx−/− mice and there 
was no evidence of more subtle behav-
ioral differences in these mice, which lim-
ited investigation into the nature of the 
defect in the brains of these mice. This 
was not altogether surprising since knock-
out of several of the genes causing auto-
somal recessive ataxias in humans fails 
to re-capitulate the phenotype in mouse 
transient R-loop accumulation, giving rise 
to transcription-associated recombination 
and genome instability. More insight into 
this was provided recently by Alzu et al.21 
who showed that Sen1p associates with 
DNA replication forks to protect their 
integrity across RNA Pol II – transcribed 
genes. Thus, Sen1p plays an important 
role in coordinating replication with tran-
scription to protect the genome. Support 
for a similar role for the human ortholog, 
senataxin, was provided recently by Yuce-
Petronczki and West22 who showed that 
senataxin localized to distinct nuclear foci 
in S/G2 phase cells and that the num-
ber of these foci increased in response to 
impaired replication. These data suggest 
that senataxin localizes to collision sites 
between the transcription apparatus and 
components of the replisome.
All of the investigations above have 
described a role for senataxin in prevent-
ing collision between DNA replication 
forks and ongoing transcription to pre-
serve genome integrity in proliferating 
cells. However, the major phenotype in 
efficiency of specific mRNAs and alter-
nate splice-site selection of both endog-
enous genes and artificial minigenes were 
altered in senataxin-depleted cells.15 A role 
for senataxin in transcription elongation 
and termination is further supported by 
a report showing that cells with senataxin 
knockdown displayed an increase in RNA 
read-through and Pol II density down-
stream of the Poly (A) site and also exhib-
ited increased levels of R-loop formation.16 
R-loops are RNA/DNA hybrids that form 
over transcription pause sites by interac-
tion with a ssDNA template behind an 
elongating Pol II complex (Fig. 1). These 
structures are potentially harmful and 
can cause genomic instability if left unre-
solved.16-18 The yeast ortholog of senataxin 
Sen1p, has also been shown to protect its 
heavily transcribed genome from R-loop-
mediated DNA damage.19 More recently, 
Hazelbaker et al.20 showed that kinetic 
competition between elongating RNA pol 
II and Sen1p helicase likely explains the 
temporal and spatial window for early Pol 
II termination. Loss of Sen1p results in 
Figure 2. Accumulation of r-loops in Setx−/− germ cells. (A) immunostaining of testes cross-sections from wildtype (+/+) and Setx knockout (−/−) mice 
with the S9.6 dnA/rnA (r-loop) antibody. nuclei were stained with Hoechst 33342. Scale bar, 100 μm. regions 1 and 2 show magnifications. (B) im-
munostaining of pachytene spermatocytes from wildtype (+/+) and Setx knockout (−/−) with S9.6 antibody shows a dramatic accumulation of r-loops 
in senataxin deficient germ cells. ScP3 was used to stain for the synaptonemal complex and identify pachytene stage cells. Scale bar, 20 μm.
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subsequently showed that senataxin had 
an essential role in spermatogenesis in 
mice and in its absence these cells failed to 
progress past the pachytene stage of pro-
phase 1 of meiosis.24 The DNA double-
strand breaks (DSB) introduced by Spo11 
in readiness for meiotic recombination 
were inefficiently repaired on autosomes, 
resulting in a failure to complete crossing-
over. During the process of crossing-over, 
autosomes remain transcriptionally active, 
so it was possible that in the absence of 
senataxin, R-loops would accumulate 
in the vicinity of unrepaired DNA DSB 
leading to collapse of Holiday junctions 
and inhibition of the crossing-over step. 
Indeed this was the case since we detected 
elevated levels of R-loops in both sper-
matocyte spreads and testes sections (Fig. 
2). Wild-type mice showed a very much 
reduced level of signal. So in the case of 
spermatocyte differentiation, the R-loops 
that accumulate in the absence of senataxin 
appear to collide with Holiday junctions 
rather than with advancing replication 
forks. We also screened for the presence 
of R-loops in the brains of Setx mutant 
mice but failed to detect these structures 
by immunofluorescence (unpublished 
data). This was not altogether surprising 
since neither DNA replication nor DNA 
recombination is taking place in this tis-
sue. It is possible that persistence of DNA 
damage in post-mitotic cells might lead 
to the accumulation of these structures, 
which in turn could contribute to the neu-
rodegenerative changes in AOA2 patients. 
However, we and others have provided 
evidence for a broader role for senataxin in 
transcription and other cellular processes. 
Senataxin plays an important role in tran-
scription termination to prevent RNA 
readthrough, which may or may not be 
related to R-loop resolution.15,16 The pres-
ence of significant readthrough of mRNA 
may lead to inefficient or aberrant protein 
synthesis and consequently cell toxicity. 
Senataxin has also been shown to play a 
role in the regulation of splicing15 and defi-
ciency of the SR splicing factor ASF/SF2 
leads to R-loop accumulation and genome 
instability.18 This in turn may interfere 
with the fidelity of the transcriptome in 
AOA2 cerebellum.
AOA2 is just one of several neuro-
degenerative disorders characterized by 
Figure 3. Protection of the genome by senataxin in proliferating vs. post-mitotic cells. (A) in 
proliferating cells, collision of the transcription apparatus (rnA Pol) with replication forks (dnA 
Pol), stalled replication forks following dnA damage exposure, or Holiday junctions during 
homologous recombination, lead to the formation and accumulation of r-loop structures. in the 
presence of senataxin, r-loops are effectively resolved by its putative dnA/rnA helicase activity, 
thus leading to normal cellular metabolism and cell survival. in the absence of senataxin, r-loops 
accumulate and impact on rnA metabolism through the alteration of mrnA splicing, the inhibi-
tion of transcription termination, the promotion of readthrough, the alteration of gene expression 
and the formation of dnA breaks. the accumulation of these defects drives genomic instability 
and ultimately cell death. (B) in contrast, in post-mitotic cells, such as neurons, the absence of 
dnA replication and homologous recombination, and the lack of r-loops accumulation suggest 
senataxin’s role in protecting the genome may be directly due to its effect on mrnA splicing, 
transcription termination and the modulation of gene expression through its interaction with 
rnA binding proteins.
patients who entered menopause in early 
adulthood which was also observed in a 
separate study.5 Ovarian failure has also 
been observed in a patient with AOA226 
and another patient had a diagnosis 
of polycystic ovarian syndrome.27 We 
models.25 However, we observed that 
Setx−/− male mice were infertile and fertil-
ity was reduced in females. While there is 
no information on male fertility in AOA2, 
there are a few reports of hypogonadism 
in females. Criscuolo et al.4 reported two 
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and DNA replication in proliferating cells. 
Resolution of R-loops is prominent in that 
role but it is evident that senataxin has a 
broader involvement in RNA process-
ing (Fig. 3). Its role in post-mitotic cells 
is not clear, but it is likely that this will 
be on some aspect of RNA metabolism 
to protect the integrity of the genome/
transcriptome. What remains intriguing 
is how mutations in a single gene SETX, 
often in close proximity to one another, 
can cause both autosomal dominant and 
recessive disorders. However, while muta-
tions in SETX give rise to what appears 
to be 4 different syndromes, it is also 
evident that there is some overlap across 
these disorders. To date, several senataxin-
interacting proteins have been identified, 
all of which are involved in some aspect of 
RNA processing.15 Mutations in some of 
these also give rise to other neurodegener-
ative disorders.28 It seems likely that these 
defects in RNA metabolism that impact 
either gene transcription, pre-mRNA 
splicing, ribonucleoprotein complex for-
mation, mRNA transport, RNA transla-
tion or RNA degradation.28 One form of 
the motor neuron disease, amyotrophic 
lateral sclerosis (ALS) is caused by defects 
in TDP-43 and FUS/TLS, both of which 
contain RNA-binding motifs29 and spi-
nal muscular atrophy (SMA) is caused by 
deletion or mutation in survival of motor 
neuron 1 (SMN1). Profound loss of splic-
esome integrity is a critical mechanism 
common to ALS and SMA.30 It is also of 
interest that we previously identified SMN 
as one of the proteins that interact with 
senataxin, pointing to an overlapping role 
in RNA processing.15
In summary, much progress has been 
made recently on the function of senataxin 
and its yeast ortholog Sen1p in resolving 
potential conflict between transcription 
17. Aguilera A, Gómez-González B. Genome instability: 
a mechanistic view of its causes and consequences. 
Nat Rev Genet 2008; 9:204-17; PMID:18227811; 
http://dx.doi.org/10.1038/nrg2268
18. Li X, Manley JL. Inactivation of the SR protein splic-
ing factor ASF/SF2 results in genomic instability. 
Cell 2005; 122:365-78; PMID:16096057; http://
dx.doi.org/10.1016/j.cell.2005.06.008.
19. Mischo HE, Gómez-González B, Grzechnik P, 
Rondón AG, Wei W, Steinmetz L, et al. Yeast Sen1 
helicase protects the genome from transcription-
associated instability. Mol Cell 2011; 41:21-32; 
PMID:21211720; http://dx.doi.org/10.1016/j.mol-
cel.2010.12.007
20. Hazelbaker DZ, Marquardt S, Wlotzka W, Buratowski 
S. Kinetic competition between RNA Polymerase II 
and Sen1-dependent transcription termination. Mol 
Cell 2013; 49:55-66; PMID:23177741
21. Alzu A, Bermejo R, Begnis M, Lucca C, Piccini 
D, Carotenuto W, et al. Senataxin associates with 
replication forks to protect fork integrity across RNA-
polymerase-II-transcribed genes. Cell 2012; 151:835-
46; PMID:23141540; http://dx.doi.org/10.1016/j.
cell.2012.09.041
22. Yüce O, West SC. Senataxin, defective in the neuro-
degenerative disorder ataxia with oculomotor apraxia 
2, lies at the interface of transcription and the DNA 
damage response. Mol Cell Biol 2013; 33:406-
17; PMID:23149945; http://dx.doi.org/10.1128/
MCB.01195-12
23. Vantaggiato C, Bondioni S, Airoldi G, Bozzato A, 
Borsani G, Rugarli EI, et al. Senataxin modulates 
neurite growth through fibroblast growth factor 8 sig-
nalling. Brain 2011; 134:1808-28; PMID:21576111; 
http://dx.doi.org/10.1093/brain/awr084
24. Becherel OJ, Yeo AJ, Stellati A, Heng EY, Luff J, 
Suraweera AM, et al. Senataxin plays an essential 
role with DNA damage response proteins in mei-
otic recombination and gene silencing. PLoS Genet 
2013; 9:e1003435; PMID:23593030; http://dx.doi.
org/10.1371/journal.pgen.1003435
25. Lavin MF. The appropriateness of the mouse model 
for ataxia-telangiectasia: Neurological defects but no 
neurodegeneration. DNA Repair (Amst) 2013; In 
press; PMID:23731731; http://dx.doi.org/10.1016/j.
dnarep.2013.04.014.
proteins function in complexes to control 
RNA metabolism and different mutations 
in the various subunits may impact differ-
ently on the function of the complex(es), 
giving rise to the heterogeneity of neu-
rodegenerative disorders observed. The 
challenge that lies ahead is to understand 
the relationships of these proteins to one 
another in the complexes and how they 
function to control processes in neurons 
and other cell types in the brain to mini-
mise the risk of neurodegeneration.
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